Clovis Oncology Inc. (NASDAQ:CLVS) was up 6.9% during mid-day trading on Monday . The stock traded as high as $18.45 and last traded at $18.44, with a volume of 1,166,468 shares trading hands. The stock had previously closed at $17.25.

Several equities research analysts recently weighed in on CLVS shares. Piper Jaffray Cos. reissued a “hold” rating on shares of Clovis Oncology in a report on Sunday, May 8th. WallachBeth Capital decreased their price objective on Clovis Oncology from $30.00 to $22.00 and set a “hold” rating for the company in a report on Monday, May 9th. Zacks Investment Research lowered Clovis Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, May 10th. Vetr lowered Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 price objective for the company. in a report on Wednesday, May 25th. Finally, Credit Suisse Group AG reissued a “hold” rating on shares of Clovis Oncology in a report on Wednesday, June 8th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $28.98.

The stock’s 50 day moving average price is $15.24 and its 200 day moving average price is $16.17. The firm’s market capitalization is $699.18 million.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.06. During the same period in the prior year, the company earned ($2.10) EPS. Analysts forecast that Clovis Oncology Inc. will post ($9.33) earnings per share for the current year.

A hedge fund recently bought a new stake in Clovis Oncology stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Clovis Oncology as of its most recent SEC filing.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.